Biomimetic, reactive oxygen species-detonable nanoclusters for antirestenotic therapy
In one aspect, the disclosure relates to nanoclusters comprising cores comprising self-assembled unimolecular nanoparticles and biomimetic membrane coatings surrounding the cores, methods of making the same, and methods of treating and preventing restenosis using same. In some embodiments, the nanoclusters can contain an anti-restenotic drug. In one embodiment, the polymers and/or copolymers of the unimolecular nanoparticles can contain a hydrophobic group such as, for example, a phenylboronic ester. In a further embodiment, the biomimetic membrane can localize the nanoclusters at sites of vascular damage, at which time reactive oxygen species (ROS) at the sites of vascular damage cleave the hydrophobic groups from the polymers and/or copolymers, increasing hydrophilicity of the polymers and/or copolymers and allowing for greater tissue penetration of the de-clustered nanoclusters and nanoparticles.
1 . A nanocluster comprising:
(a) a core comprising self-assembled unimolecular nanoparticles, wherein the core, upon exposure to at least one reactive oxygen species (ROS), disassembles back into unimolecular nanoparticles;
(b) a biomimetic membrane coating surrounding the core; and
(c) a block copolymer comprising units derived from a lactide monomer, wherein the block copolymer comprises H40-polylactide-block-poly{methacrylic acid-ran-2-(methacryloyloxy)-N,N-dimethyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]ethan-1-aminium}.
2 . The nanocluster of claim 1 , wherein the biomimetic membrane comprises a platelet-derived membrane, a macrophage-derived membrane, a leukocyte-derived membrane, a mesenchymal stem cell-derived membrane, an exosomal membrane, a liposomal membrane, or any combination thereof.
3 . The nanocluster of claim 1 , wherein the unimolecular nanoparticles comprise a hydrophobic group, wherein the hydrophobic group comprises a phenylboronic ester.
4 . The nanocluster of claim 1 , wherein the biomimetic membrane coating is derived from human cells, exosomes, or liposomes.
5 . The nanocluster of claim 4 , wherein the human cells comprise platelets, macrophages, leukocytes, mesenchymal stem cells, endothelial cells, or endothelial progenitor cells.
6 . The nanocluster of claim 1 , further comprising a drug, wherein the drug comprises an anti-restenotic drug.
7 . The nanocluster of claim 6 , wherein the anti-restenotic drug comprises RVX-208, RVX-297, resveratrol, JQ1, OTX-015, ZEN-3694, I-BET762, ABBV-744, ARV-825, sirolimus, everolimus, tacrolimus, paclitaxel, GCN2-IN-1, GSK2606414, GSK2656157, halofuginone, CI-amidine, D-CI-amidine, CI4-amidine, CAY10723, GSK484, EZP-6438, A-395, EED226, tubastatin, SIS3, centrinone B, or any combination thereof.
8 . The nanocluster of claim 1 , wherein the unimolecular nanoparticles have an average diameter of from about 10 to 70 nm.
9 . A nanocluster composition comprising a plurality of individual nanoclusters according to claim 3 .
10 . The nanocluster composition of claim 9 , wherein the individual nanoclusters have an average diameter of from about 100 to 250 nm.
11 . A method for treating at least one vascular damage event in a subject, the method comprising administering the nanocluster composition of claim 9 to a subject.
12 . The method of claim 11 , wherein the biomimetic membrane localizes the nanoclusters at one or more sites of vascular damage in the subject.
13 . The method of claim 11 , wherein the at least one vascular damage event comprises restenosis, aneurysm, deep vein thrombosis, or any combination thereof.
14 . The method of claim 11 , wherein administering the nanocluster composition comprises intravenous injection of a unit dose of the nanocluster composition.
15 . The method of claim 14 , wherein the unit dose of the nanocluster composition comprises from about 5 to about 50 mg of a drug per kg of body weight of the subject.
16 . The method of claim 15 , wherein the drug comprises RVX-208, RVX-297, resveratrol, JQ1, OTX-015, ZEN-3694, I-BET762, ABBV-744, ARV-825, sirolimus, everolimus, tacrolimus, paclitaxel, GCN2-IN-1, GSK2606414, GSK2656157, halofuginone, CI-amidine, D-CI-amidine, CI4-amidine, CAY10723, GSK484, EZP-6438, A-395, EED226, tubastatin, SIS3, centrinone B, or any combination thereof.
17 . The method of claim 11 , wherein one or more reactive oxygen species at the one or more sites of vascular damage cleaves the hydrophobic end group, wherein cleavage of the hydrophobic end group triggers release of one or more water soluble byproducts and a transition of the unimolecular nanoparticles to hydrophilic nanoparticles.